LIVN:NGS-LivaNova PLC (USD)

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 63.2

Change

+1.77 (+2.88)%

Market Cap

USD 2.11B

Volume

0.46M

Analyst Target

USD 65.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

LivaNova PLC is a medical technology company formed by the merger of Sorin S.p.A, engaged in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-0.44 (-0.61%)

USD 29.04B
PODD Insulet Corporation

-1.79 (-0.77%)

USD 16.66B
BRKR Bruker Corporation

+0.46 (+0.79%)

USD 9.04B
MASI Masimo Corporation

+1.84 (+1.30%)

USD 7.53B
TMDX TransMedics Group Inc

-6.58 (-7.44%)

USD 4.17B
AXNX Axonics Modulation Technologie..

+0.05 (+0.07%)

USD 3.59B
PRCT Procept Biorobotics Corp

-3.66 (-3.79%)

USD 3.50B
QDEL Quidel Corporation

+0.62 (+1.62%)

USD 2.67B
NARI Inari Medical Inc

-2.08 (-4.23%)

USD 2.57B
IRTC iRhythm Technologies Inc

-1.23 (-1.60%)

USD 2.36B

ETFs Containing LIVN

XHE SPDR® S&P Health Care Eq.. 2.00 % 0.35 %

+0.24 (+0.27%)

USD 0.21B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 22.15% 80% B- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.15% 80% B- 83% B
Trailing 12 Months  
Capital Gain 37.21% 85% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.21% 85% B 82% B
Trailing 5 Years  
Capital Gain -12.08% 77% C+ 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.08% 77% C+ 39% F
Average Annual (5 Year Horizon)  
Capital Gain -0.80% 50% F 43% F
Dividend Return -0.80% 50% F 39% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 37.88% 78% C+ 47% F
Risk Adjusted Return -2.10% 50% F 39% F
Market Capitalization 2.11B 94% A 86% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 173.53 18% 7%
Price/Book Ratio 2.24 55% 44%
Price / Cash Flow Ratio 44.89 8% 6%
Price/Free Cash Flow Ratio 84.04 4% 3%
Management Effectiveness  
Return on Equity -2.59% 85% 56%
Return on Invested Capital 10.95% 85% 80%
Return on Assets 2.64% 86% 78%
Debt to Equity Ratio 44.50% 51% 44%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector